Breaking up long periods of sitting in the evening can result in lower blood sugar and insulin levels in healthy adults, a new University of Otago study has found.
Mar 29, 2023
0
8
Type 2 diabetes (T2D) accounts for more than 90% of the confirmed diabetes cases. It has become a common metabolic disease and is expected to affect 380 million people worldwide by 2025. Currently, clinically used diagnostic ...
Mar 10, 2023
0
5
Acute myocardial infarction (AMI) causes a massive loss of cardiomyocytes, leading to heart failure with fibrosis, stiffening of the heart and loss of function. Diabetes mellitus (DM) is a well-known risk factor for AMI. ...
Feb 10, 2023
0
20
It's been used for thousands of years to treat a variety of illnesses—and now acupuncture could also help fight one of the 21st century's biggest health challenges.
Aug 2, 2022
0
3
Random plasma glucose tests could be used to predict which patients will develop diabetes, according to a study of Veterans Affairs treatment data. Researchers from several VA systems showed that levels of glucose found during ...
Jul 19, 2019
0
7
(HealthDay)—Individuals who develop diabetes or prediabetes have elevated fasting plasma glucose (FPG) at least 10 years before diagnosis, according to an observational study recently published in the Journal of the Endocrine ...
Oct 22, 2018
0
10
Researchers used continuous glucose monitoring (CGM) to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes (T2D) and found significant reductions in mean ...
Oct 1, 2018
1
1
(HealthDay)—Mini-dose glucagon (MDG) is an effective approach for preventing exercise-induced hypoglycemia in patients with type 1 diabetes, according to a study published online May 18 in Diabetes Care.
May 30, 2018
0
1
(HealthDay)—There is an inverse association for plasma 25-hydroxyvitamin D (25[OH]D) concentration with diabetes risk, according to a study published online April 19 in PLOS ONE.
May 23, 2018
0
2
(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.
Dec 26, 2017
0
6
